 by
Ian Spatz
|
A non-governmental advisory body has begun to define one of the most important elements of last year’s health reform law. A committee of the Institute of Medicine will develop recommendations to the Department of Health and Human Services on how to define an “essential health benefit.” The ultimate resolution of this question, which may not... Read the rest of this entry »
by
Ian Spatz
|
Global health issues, especially those affecting the world’s poor, rarely gain anywhere near the attention that the U.S. public and policymakers give to domestic concerns. However, in one small corner of the current health reform discussion, there is a golden opportunity not only to reduce U.S. health care costs but also to improve the health... Read the rest of this entry »
by
Ian Spatz
|
What is the appropriate price for a biotechnology product? Jamie Robinson’s thoughtful post touches all the right bases in arguing that discussing the role of value in pricing is far preferable to discussing the cost of research, development and production.
Read the rest of this entry »
